Literature DB >> 33221389

Development of pyrimidone D1 dopamine receptor positive allosteric modulators.

Kathryn D Luderman1, Prashi Jain2, R Benjamin Free1, Jennie L Conroy1, Jeffrey Aubé3, David R Sibley4, Kevin J Frankowski5.   

Abstract

MLS1082 is a structurally novel pyrimidone-based D1-like dopamine receptor positive allosteric modulator. Potentiation of D1 dopamine receptor (D1R) signaling is a therapeutic strategy for treating neurocognitive disorders. Here, we investigate the relationship between D1R potentiation and two prominent structural features of MLS1082, namely the pendant N-aryl and C-alkyl groups on the pyrimidone ring. To this end, we synthesized 24 new analogues and characterized their ability to potentiate dopamine signaling at the D1R and the closely related D5R. We identified structure-activity relationship trends for both aryl and alkyl modifications and our efforts afforded several analogues with improvements in activity. The most effective analogues demonstrated an approximately 8-fold amplification of dopamine-mediated D1R signaling. These findings advance the understanding of structural moieties underlying the activity of pyrimidone-based D1R positive allosteric modulators.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cognitive decline therapeutics; Copper-mediated amidation; GPCR modulation

Mesh:

Substances:

Year:  2020        PMID: 33221389      PMCID: PMC8380033          DOI: 10.1016/j.bmcl.2020.127696

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  13 in total

1.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory.

Authors:  Susheel Vijayraghavan; Min Wang; Shari G Birnbaum; Graham V Williams; Amy F T Arnsten
Journal:  Nat Neurosci       Date:  2007-02-04       Impact factor: 24.884

Review 2.  The dopaminergic system in hypertension.

Authors:  Chunyu Zeng; Meng Zhang; Laureano D Asico; Gilbert M Eisner; Pedro A Jose
Journal:  Clin Sci (Lond)       Date:  2007-06       Impact factor: 6.124

Review 3.  Emerging paradigms in GPCR allostery: implications for drug discovery.

Authors:  Denise Wootten; Arthur Christopoulos; Patrick M Sexton
Journal:  Nat Rev Drug Discov       Date:  2013-08       Impact factor: 84.694

4.  Discovery of D1 Dopamine Receptor Positive Allosteric Modulators: Characterization of Pharmacology and Identification of Residues that Regulate Species Selectivity.

Authors:  Martin A Lewis; Lisa Hunihan; John Watson; Robert G Gentles; Shuanghua Hu; Yazhong Huang; Joanne Bronson; John E Macor; Brett R Beno; Meredith Ferrante; Adam Hendricson; Ronald J Knox; Thaddeus F Molski; Yan Kong; Mary Ellen Cvijic; Kristin L Rockwell; Michael R Weed; Angela M Cacace; Ryan S Westphal; Andrew Alt; Jeffrey M Brown
Journal:  J Pharmacol Exp Ther       Date:  2015-06-24       Impact factor: 4.030

Review 5.  Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation.

Authors:  Adrian Hall; Laurent Provins; Anne Valade
Journal:  J Med Chem       Date:  2018-12-27       Impact factor: 7.446

6.  Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Authors:  Kathryn D Luderman; Jennie L Conroy; R Benjamin Free; Noel Southall; Marc Ferrer; Marta Sanchez-Soto; Amy E Moritz; Blair K A Willette; Tim J Fyfe; Prashi Jain; Steve Titus; Lisa A Hazelwood; Jeffrey Aubé; J Robert Lane; Kevin J Frankowski; David R Sibley
Journal:  Mol Pharmacol       Date:  2018-08-01       Impact factor: 4.436

7.  Synthesis and Pharmacological Characterization of 2-(2,6-Dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a Potent, Subtype Selective, and Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor.

Authors:  Junliang Hao; James P Beck; John M Schaus; Joseph H Krushinski; Qi Chen; Christopher D Beadle; Paloma Vidal; Matthew R Reinhard; Bruce A Dressman; Steven M Massey; Serge L Boulet; Michael P Cohen; Brian M Watson; David Tupper; Kevin M Gardinier; Jason Myers; Anette M Johansson; Jeffery Richardson; Daniel S Richards; Erik J Hembre; David M Remick; David A Coates; Rajni M Bhardwaj; Benjamin A Diseroad; David Bender; Greg Stephenson; Craig D Wolfangel; Nuria Diaz; Brian G Getman; Xu-Shan Wang; Beverly A Heinz; Jeff W Cramer; Xin Zhou; Deanna L Maren; Julie F Falcone; Rebecca A Wright; Stephen N Mitchell; Guy Carter; Charles R Yang; Robert F Bruns; Kjell A Svensson
Journal:  J Med Chem       Date:  2019-09-30       Impact factor: 7.446

8.  Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor.

Authors:  Xushan Wang; Beverly A Heinz; Yue-Wei Qian; Joan H Carter; Robert A Gadski; Lisa S Beavers; Sheila P Little; Charles R Yang; James P Beck; Junliang Hao; John M Schaus; Kjell A Svensson; Robert F Bruns
Journal:  Mol Pharmacol       Date:  2018-08-15       Impact factor: 4.436

9.  Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency.

Authors:  M M Lewis; V J Watts; C P Lawler; D E Nichols; R B Mailman
Journal:  J Pharmacol Exp Ther       Date:  1998-07       Impact factor: 4.030

Review 10.  The neuropsychopharmacology of fronto-executive function: monoaminergic modulation.

Authors:  T W Robbins; A F T Arnsten
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

View more
  3 in total

1.  Ligand recognition and biased agonism of the D1 dopamine receptor.

Authors:  Xiao Teng; Sijia Chen; Yingying Nie; Peng Xiao; Xiao Yu; Zhenhua Shao; Sanduo Zheng
Journal:  Nat Commun       Date:  2022-06-08       Impact factor: 17.694

Review 2.  The Impact of the Secondary Binding Pocket on the Pharmacology of Class A GPCRs.

Authors:  Attila Egyed; Dóra Judit Kiss; György M Keserű
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

3.  Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D1 Receptor.

Authors:  Tim J Fyfe; Peter J Scammells; J Robert Lane; Ben Capuano
Journal:  Molecules       Date:  2021-06-22       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.